Sentences with phrase «cell therapy processing»

Not exact matches

«Used in cancer therapy, this process could increase the impact of a treatment by heating the cancer cells while introducing the drug compound into the tumor.»

One of the molecular mysteries hindering development of regenerative therapy for muscles is uncovering the precise genetic and molecular processes that cause skeletal muscle stem cells (called myoblasts) to fuse and form the striated muscle fibers that allow movement.

Along with the study's co-first authors, Drs. Aayoung Hong and Gatien Moriceau, Lo hypothesized that if they could identify the key tumor cell processes triggered by withdrawal of MAPK inhibitors, then scientists can exploit these process with existing or investigational drugs to trigger the maximal levels of tumor cell death immediately following cessation of the initial therapy.

Setton says the multistep process her lab used to derive NP - type cells from the hiPSCs provides the necessary quality control as scientists seek additional uses for stem cell therapies.

One clinical trial involves the drug CGF166, a one - time gene therapy, which, if proven successful in humans, could regenerate new hair cells within the cochlea that can signal the part of the brain that processes sound.

A specific genetic marker influences response to therapy in the early stages of RA; a link thought to be due to the gene activating a cell - signalling protein involved in the inflammatory disease process.

The journal's home page explains that translational medicine «builds on basic research advances — studies of biological processes using cell cultures, for example, or animal models — and uses them to develop new therapies or medical procedures.»

If researchers can unlock the secrets of this cellular process, therapies that replace diseased cells with healthy ones may one day be possible — brain - cell transplants to combat Alzheimer's, for instance, or even the creation of whole organs from scratch.

Understanding how cancer cells are able to metastasize — migrate from the primary tumor to distant sites in the body — and developing therapies to inhibit this process are the focus of many laboratories around the country.

Now, scientists reporting April 12 in Cell Metabolism have discovered a protein that activates the maturation process in vitro, overcoming this longstanding obstacle in diabetes therapy development.

Another view is that tumors can become resistant to therapy by a process called cell fate decision, by which some tumor cells are killed by therapy and others become cancer stem cells.

If CTL019 is approved, the Swiss pharmaceutical giant plans to dole it out from about 30 preapproved sites, each trained in the multi-step process of harvesting cells, handling the product, and treating patients for the feverish and often life - threatening immune response that usually accompanies CAR - T therapy.

Currently, there is no cure to stop or reverse any form of muscle - wasting disorders — only medication and therapy that can slow the process,» said Vittorio Sartorelli, M.D., chief of the Laboratory of Muscle Stem Cells and Gene Regulation and deputy scientific director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

Because diseases such as cancer tend to evade detection by T - cells» receptors, allowing a tumor to grow unchecked, scientists have long sought «intel» on this process as a means of developing therapies that target malignant cells, but leave healthy cells alone.

The research team found that when a particular mitochondrial fission protein (GTPase dynamin - related protein - 1 — Drp1) was blocked using either gene - therapy or a chemical approach in experimental models of PD in mice, it reduced both cell death and the deficits in dopamine release — effectively reversing the PD process.

The complete list is: the Food Research Center; the Center for Research, Teaching, and Innovation in Glass; the Center for Research and Development of Functional Materials; the Brazilian Research Institute for Neuroscience and Neurotechnology; the Center for Research on Inflammatory Diseases; the Center for Research and Innovation in Biodiversity and Drug Discovery; the Center for Research on Toxins, Immune Response, and Cell Signaling; the Research, Innovation and Dissemination Center for Neuromathematics; the Center for Research in Mathematical Sciences Applied to Industry; the Obesity and Co-Morbidities Research Center; the Center for Cell - Based Therapy; the Center for Metropolitan Studies; the Human Genome and Stem - Cell Research Center; the Center for Computational Science and Engineering; the Center for Research on Redox Processes in Biomedicine; the Center for the Study of Violence; and the Optics and Photonics Research Center.

A promising type of therapy called differentiation therapy targets these malignant cells so that they can resume the process of differentiating into mature cells.

«For a stem cell therapy for Duchenne to move forward, we must have a better understanding of the cells we are generating from human pluripotent stem cells compared to the muscle stem cells found naturally in the human body and during the development process.»

In contrast with most other reviews, it covers all major corneal cell types in a comprehensive way, showing similarities and differences in the healing process and the usage of stem cells for therapy.

A better understanding of the process that enables these cancer cells to remodel bone may aid in the search for new therapies.

With so much work needed in studying the nature of stem cells and using them to study disease processes, therapies based on ES cells seem very far down the line, noted Lorenz Studer of Memorial Sloan - Kettering Cancer Center in New York, who pointed out that so far there have only been two published papers on therapeutic cloning, both of them in mice.

Instead we can use the epigenetic clock to monitor their cells» aging rate and to evaluate which therapies slow the biological aging process,» explained Horvath.

«The successful retrieval of memories in AD mice by increasing the number of spines for normal memory processing only in the memory cells, rather than in a broad population of cells, highlights the importance of highly - targeted manipulation of neurons and their circuits for future therapies.

Contact the Okyanos team to begin the process of determining if cell therapy is appropriate for your condition.

Although basic research documents that these cells die by a multi-factorial process, the vast majority of therapies tested to date, or in development, are likely to fail because they target only a single injury pathway.

Adult stem cell therapy is the process of isolating the stem and regenerative cells found in patients» own body fat and re-introducing them into damaged zones of the body and / or systemically to address underlying factors of chronic, degenerative disease.

Better understanding of the beta - cell proliferation process eventually may lead toward therapies for diabetes patients, whose supplies of these cells often shrink over time, says Rohit Kulkarni, M.D., Ph.D., a Joslin Senior Investigator and senior author on a paper about the work published in the journal Cell Metabolcell proliferation process eventually may lead toward therapies for diabetes patients, whose supplies of these cells often shrink over time, says Rohit Kulkarni, M.D., Ph.D., a Joslin Senior Investigator and senior author on a paper about the work published in the journal Cell MetabolCell Metabolism.

Working with the research group led by Vijay G. Sankaran, M.D., Ph.D., of Boston Children's Hospital and the Broad Institute, Rajiv K. Khajuria, a doctoral student at Charité's Berlin - Brandenburg School for Regenerative Therapies, studied the molecular processes involved in the differentiation of stem cells and their development into mature blood cells.

Learn about the process behind Penn's CAR - T cell therapy, the first - ever cancer treatment that genetically alters a patient's own immune cells to target and destroy cancer cells.

Supported by: Hear from leading expert Dr David DiGiusto, Stanford University School of Medicine, USA, as he shares his extensive experience in developing and optimizing manufacturing processes for cell and gene therapy products including:

These so - called «living drugs» — injected T cells genetically modified to better recognize and kill tumor cells through a perpetual process of cell renewal and expansion — are revolutionizing cancer treatment, with the first two FDA approvals of such gene - altering therapies occurring in just the last two months.

The model organism offers a way to better understand stem cell - driven regeneration processes, an important step in regenerative medicine and the promise of therapies to repair or replace damaged human tissue.

This is followed by a presentation by Dr Alaina Schlinker, Fresenius Kabi, as she discusses practical approaches to addressing some of the key processing challenges for cell and gene therapy products.

The cell processing track aims at reproducible, safe and sustainable methods applicable in manufacturing settings for cell - based products intended for cellular therapy.

In the latest episode of #TalkingRegMed, Alice Philipson, University of Leeds, discusses her research into the development of a device for processing mesenchymal stem cells (MSCs) for cell therapies.

«The successful retrieval of memories in AD mice by increasing the number of spines for normal memory processing only in the memory cells, rather than in a broad population of cells, highlights the importance of highly - targeted manipulation of neurons and their circuits for future therapies,» said Tonegawa in a statement.

Scientists publishing in the journal Cell Stem Cell have reported the production of functional human oocytes from discarded genetic material, a process which they suggest could one day assist in fertility treatment or mitochondrial replacement therapy.

The rapidly developing global cell therapy market poses numerous industry challenges for drug development, process scalability, commercialization, and patient safety.

While many important developments impacted the field, two that garnered significant public, political and scientific attention in 2016 were the proliferation of clinics using unproven stem cell «therapies,» and the steps forward in therapeutic modification of human oocytes (unfertilized eggs) through a process called mitochondrial replacement therapy (MRT).

Cell Therapy Catapult will develop a scalable manufacturing and differentiation process for AST - VAC2 in order to support the downstream demands of clinical trials and ultimately commercialization.

For many CAR - T and T - cell receptor (TCR) cell therapies, there's a significant need to scale - up processes.

Allogeneic cell therapies involving primary cell types such as bone marrow mesenchymal stromal / stem cells (BM - MSCs), hematopoietic stem and progenitor cells (HSPCs), and T and natural killer (NK) cells for immunotherapy applications are especially challenging because of the vigorous process of screening...

Afterward, senoablative therapy can be initiated again to mop up any senescent cells not eliminated by physiological processes, and to resume clearance of the backlog of senescent cells that existed before therapy was temporarily suspended.

Researchers hope to one day use such a process in humans to create customized stem - cell therapies for individual patients.

Because they stimulate the immune system rather than introducing an agent or process that can kill healthy cells along with the malignant ones, these therapies — which include commonly prescribed treatments such as trastuzumab (Herceptin), pembrolizumab (Keytruda) and nivolumab (Opdivo)-- have been noteworthy not only for their effectiveness but for their tolerability.

«With the new stem cell model, however, we hope eventually to put together a much more detailed picture of this process of repeat expansion and gene silencing, and that should put us in a good position to devise optimal therapies,» Gottesfeld said.

«With the new stem cell model, we hope eventually to put together a much more detailed picture of this process of repeat expansion and gene silencing, and that should put us in a good position to devise optimal therapies,» says Professor Joel Gottesfeld.

The goal is to use these tools to gain a deeper understanding of the disease processes in cancer, diabetes, heart disease and mental health, and ultimately to try and find safer and more effective ways of using stem cells in medical research and therapy.

These rECs could be valuable for cell therapy, personalized disease investigation, and exploration of the reprogramming process.

It is conceivable the techniques being developed might have some application in future stem cell therapies in humans where a cloning process was used to generate particular tissues for transplantation.